Dr, Peking University, China
Dr. Rongbin Li is an accomplished immunologist affiliated with the Department of Immunology at Peking University, Beijing, China. She specializes in colitis-associated carcinogenesis and has made significant contributions to advancing knowledge in immunology and cancer research. With a focus on colorectal cancer, her groundbreaking research has led to innovations, including the identification of CMTM3 as a therapeutic target for inflammatory bowel disease and colorectal cancer. Dr. Li’s work is published in top journals, with her recent research recognized by the National Natural Science Foundation of China (NSFC).
Profile
Orcid
Education 🎓:
Dr. Rongbin Li holds a Ph.D. in Immunology from Peking University (2019-2024) where she focused on molecular mechanisms in cancer development. She also earned a Bachelor of Medicine in Clinical Medicine from Hebei University of Engineering (2014-2019), providing her a solid foundation in clinical diagnostics, pathophysiology, and immunology. Her academic journey has been marked by her keen interest in combining laboratory research with real-world medical applications, particularly in cancer research.
Experience 💼:
Dr. Li has gained extensive research experience at Peking University and has collaborated with prestigious institutions like Peking University Third Hospital. Her projects have received substantial support, including funding from the National Natural Science Foundation of China (NSFC). Dr. Li played a central role in projects focusing on CMTM3 as a target for colorectal cancer therapy. She has authored several high-impact publications and presented her work at national conferences, including the 15th National Congress of Immunology in November 2023, solidifying her role as a leader in immunology and cancer research.
Awards and Honors 🏆:
Dr. Rongbin Li’s research excellence has been recognized through various prestigious awards and honors. Notably, her research on CMTM3 as a therapeutic target for colorectal cancer has led to a patent under process. She has received funding from the National Natural Science Foundation of China for her innovative projects. Additionally, Dr. Li’s contribution to the field has been acknowledged at multiple scientific conferences, where her oral presentations have earned accolades, further establishing her reputation in the scientific community.
Research Focus 🔬
Dr. Li’s primary research focus is on colitis-associated carcinogenesis. Her work investigates the molecular mechanisms by which CMTM3 accelerates cancer progression in inflammatory bowel disease (IBD). By studying the interactions between CMTM3 and clathrin, her research aims to uncover new therapeutic targets for colorectal cancer. Through her work, Dr. Li is making significant strides toward developing biologics and small molecules aimed at treating IBD and colorectal cancer, potentially revolutionizing cancer therapies.
Conclusion 🏅
Dr. Rongbin Li’s research is transformative, especially regarding colorectal cancer and IBD therapies. His innovative work on CMTM3 shows immense potential for medical advancement. Though there are opportunities to increase his international exposure and consultancy involvement, his scholarly output, dedication, and patent work solidify him as a strong contender for the Young Scientist Award.
Publication
Title: CMTM3 promotes colitis-associated carcinogenesis via CLTC stabilization and modulation of VE-cadherin
Authors: Rongbin Li, Yuan Liu, Qiyao Liu, Zixia Guo, Bingsu Wang, Sihua Huang, Zelin Wang, Fujun Liu, Yifan Zhou, Pingzhang Wang, et al.
Journal: Cellular and Molecular Gastroenterology and Hepatology
Year: 2025
DOI: 10.1016/j.jcmgh.2025.101528
Source: Crossref